drugset / Trial / NCT02724254
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
Timeline
- Start
- 2016-01
- Primary completion
- 2018-05
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP611074 | Small molecule | 5 % | Topical |
| Subject | AP611074 | Small molecule | 100 mg | Topical |